SRF Limited (503806) Earnings Call Transcript

Ladies and gentlemen, good day, and welcome to SRF Limited Q2 and H1 FY '21 Earnings Conference Call hosted by Ambit Capital. [Operator Instructions] Please note that this conference is being recorded. I now hand the conference over to Mr. Ritesh Gupta from Ambit Capital. Thank you, and over to you, sir.

Hi, everyone. Good afternoon. So we have with us SRF management joined by Mr. Rahul Jain, President and Chief Financial Officer, SRF Limited; and Ms. Nitika Dhawan, Head of Corporate Communications, SRF Limited. I welcome both of them on the call. So Nitika, do you want to introduce, set the context and go forward?

Nitika?

Ms. Dhawan, your line is in talk mode. You can go ahead, please. Ms. Dhawan, we are not able to hear you.

Rahul, would you want to start with the opening remarks?

I will start, Ritesh. I think there is a problem with Nitika's line. But before I begin the call, I would just like to point out that some of the statements made in this call will be forward-looking, and a disclaimer to this effect has been included in the earnings presentation shared with you earlier. Thank you, guys. and I'll now start the call. Good afternoon, everyone, and I extend a warm welcome to you all, and thank you for joining us today on SRF's Q2 and H1 FY '21 Earnings Conference Call. I hope you, your team and loved ones are safe and in good health. I will initiate the call by briefly taking you through the key operational highlights for the quarter under review, following which we will open the forum to have a detailed Q&A session. I am pleased to share that we have delivered a robust performance during the quarter, primarily driven by strong results reported in the specialty chemicals and the packaging films businesses. In Q2 FY '21, gross operating revenue increased 21% quarter-on-quarter to INR 2,101 crores. EBITDA increased by 66% Q-on-Q to INR 592 crores, with EBITDA margins expanding to 28.2%. Profit after tax grew by 57% Q-on-Q to INR 306 crores during the quarter under review. All of the above numbers are on continuing basis, excluding the sale of Engineering Plastics business and the shutdown of Technical Textiles business in Thailand, which happened in Q2 FY '20. Let me now take you through the segmental performance. During the quarter, the Specialty Chemicals business delivered a robust performance on account of healthy demand and higher volumes for most of our products, which led to better operating leverage playing out. We also witnessed improved traction for our products that cater to the fungicides and the herbicides categories of agrochemicals. Our consistent emphasis on cost reduction via process enhancement and optimum utilization of resources led to improved operational performance. During the quarter, we successfully launched one product each in the pharma and agro segments. An increase in product portfolio will further help us deepen engagement with our global customers. We are well placed in Indian Specialty Chemicals industry with increasing opportunities. As we continue to deliver the benefits of more complex chemicals and specialty products to our global customers, we have undertaken new CapEx plans to expand and enhance our capacity. The Board of Directors approved an investment of INR 17.5 crores for setting up of a dedicated facility to produce 200 MT per year of P16 specialty product at our Dahej facility in the meeting held yesterday. This is a key building block for some of our products that are witnessing demand expansion. Given the performance in H1 for the business, we believe that FY '21 growth that we can now achieve would certainly be north of 25%. The Fluorochemicals business on the other hand witnessed a subdued performance on a year-on-year basis owing to weak demand for refrigerants from the automobile and air conditioning segments. This was on account of flat amount due to softening in economic activity and low prices of refrigerants globally. However, on a sequential basis, there seems to be an uptick in the business. And going forward, we expect gradual recovery in demand for refrigerants, led by demand from OEMs across categories. Passenger vehicle production was low during the quarter and H1, however, which is expected to recover -- this is expected to recover in the coming quarters. Similarly, demand for AC is also projected to improve hereon. Most of you are aware that the Director General of Trade Remedies, DGTR, has initiated antidumping duty investigation on R32 and refrigerant gas plants. And recently, there has been a ban on import of recharge air conditioners. Such trade measures should lead to better utilization of available Indian capacity in the short term to medium term. I am also happy to inform you that we recently commenced commercial supplies of the proprietary R-467 to some of our customers in the Middle East. Over the years, SRF has emerged as a dominant player in this industry. We have made prudent investment in capacities, R&D, innovation and technology that has established us as 1 of the few fully backward integrated producers globally. With expanded capacity and an improving demand scenario, we are well positioned to further strengthen our leadership position in the industry and deliver a superior performance going forward. In addition to the above, the Board approved 2 projects related to future water security and setup of thermal oxidation facilities at our chemical complex in Dahej. We have integrated sustainability across all our operations and [crossed] from the robust foundations that we have built over time. These projects will be implemented over a 3-year period on a modular basis. The projects are aimed at minimizing the environmental impact of the chemicals business, thereby setting global benchmarks for our site and ensuring future sustainability. It is also important to note that these investments are ROI-accretive, and we continue to -- as we continue to introduce novel and cutting-edge technologies to the world with a strong emphasis on intellectual property creation and protection. We are on track to achieve our yearly growth targets and will continue to successfully leverage SRF inherent R&D and innovation capabilities to develop long-term profitable businesses. Coming on to the Packaging Films business. The business performed exceedingly well during the quarter on account of healthy volumes and improved margins from BOPET and BOPP segment. The exports and domestic market in the BOPP and BOPET segment delivered steady contribution to the performance. As mentioned in the previous call, EBIT margin reduced on a quarter-on-quarter basis due to expanded capacities coming on board, but still remained healthy at 29.6%. We continue to focus on improving the inherent strength of the business, which includes cost leadership, expanding new product offerings through innovation, increasing contribution from value-added products and enhancing our relationship with the end customers. Our newly commissioned BOPET film line at Thailand also delivered a strong performance during the quarter, where it has now ramped up to almost 90% of its weighted capacity over a very short tenure. The related resin plant in Thailand will also likely to be commissioned in the ensuing quarter. On the operational front, we also launched 4 new products in Q2 FY '21. Our BOPET value-added product sales also increased when compared to CPLY by about 20%. I am glad to share that the Board yesterday approved a CapEx of approximately INR 424 crore for setting up a second BOPP film line in Indore, which will be implemented over a period of next 20 months. With the COVID-19 pandemic emphasizing the important [indiscernible] in the sanitation, we have seen a surge in hygienic packaging material requirements. Given our strong track record of successfully commissioning lines over the past few years at attractive paybacks, we are confident of an overall -- on an overall basis that we should be able to deliver healthy IRR for this investment as well. Moving on to our Technical Textiles Business segment. We witnessed an improved performance in the quarter under review. This was backed by faster-than-expected recovery in the domestic tire industry [Audio Gap ] the domestic tire industry began to rapidly recover and helped us gain strong momentum in the business. On the Belting Fabric front, the performance was in line with expectations as the value-added products aided higher growth in sales. In Polyester Yarn segment, the performance was impacted due to domestic slowdown and intense competition from Chinese players. However, we expect a robust demand for yarn in the geo textiles and sea build segments in the coming few quarters. Lastly, in our Others segment, coated fabrics delivered the best-ever results and continue to maintain its leadership position in the domestic market. Laminated self fabric segment emerged as the market leader, both in terms of volume and pricing. However, margins do remain under pressure owing to low demand and continuing oversupply situation. I am also pleased to share that recently company [indiscernible] INR 750 crores from institutional investors by way of a qualified institutional placement and many marquee names participated at the issuance. We believe this is SRF's future growth capital. Going ahead, we plan to use these proceeds mainly for finding suitable organic growth opportunities over the next 12 to 18 months, where we believe that the CapEx intensity can be increased significantly given our current engagement with the customers. At this juncture, we believe it is important for us to diversify into newer, more complex chemistries beyond provision that would enable the company to be present across the entire [indiscernible]. As we think about our future growth opportunities, we are focused on harnessing our R&D capabilities and our world-class manufacturing facility further to deliver products that compete with the best in the world, address some of the world's most pressing needs in agrochemical and pharmaceutical sector. SRF continues to maintain liquidity through multiple needs, money market activities and debt management throughout the quarter as we achieved our strong balance sheet position. Effective liquidity initiatives have resulted in lower interest payments and lower overall net debt status by about INR 350 crores. Our balance sheet and P&L leverage parameters remained strong and are further aided by the recent capital raise. I am happy to share that our chemicals facility in Bhiwadi, Rajasthan, has been recognized with the ICC award for excellence in management of health and safety for 2019 by the Indian Chemical Council. We are proud of our team's consistent and substantial efforts towards making SRF a sustainable and safe organization for all stakeholders. Our diligent EHS team believes that all accidents are preventable, and they strive to eliminate any such occurrences through effective site management and complete ownership. We continue to strengthen our community outreach programs. Our CSR arm, SRF Foundation, conducted its pilot program in academics through a blended mode of online and off-line classes, reaching more than 12,000 students in 140 government schools across 7 states in the quarter. In conclusion, SRF has managed to address several external challenges during these unprecedented times on the back of our innovative technological advancements propelled by our strong R&D team. We aim to deliver a consistent performance and deliver value to all our stakeholders in the future with a strong system in place and unparalleled R&D capabilities. Furthermore, we continue to build a deeper relationship with all our customers and expand our global footprint as we share an everlasting SRF brand going forward. On that note, I conclude my remarks and would be glad to discuss any questions, comments or suggestions that you may have. I would now like to ask the moderator to open the line for the Q&A session. Thank you very much.

[Operator Instructions] The first question is from the line of Rohit Sinha from Emkay Global.

Congratulations for a good set of numbers. So firstly, I would like more on the R gas side, what is the utilization level in R gas in the Q2 FY '21? And have we reached the pre-COVID level? Or what could be the peak utilization level basically in R gas segment?

Rohit, we have not reached pre-COVID levels. Again, this is a kind of a business which is kind -- let's say, seasonal to a certain extent. Now Q1 typically is the best season for the business where, because of the summer months, the demands are on the high. Again, Q1, we saw the burnout happening because of COVID. I can tell you that R32 capacity that we have is kind of -- at the end of September was kind of full. R134a, we are still looking to, let's say, take the capacity to pre levels over a period of time. We believe as the domestic demand, let's say, kind of kicks in, we should see much larger numbers on that side also. On 125, which is the third HFC, we see the fact that -- Rohit, if you could just mute yourself, there is just a lot of background noise. Yes. So on 125, there are certain challenges on pricing. But you are -- as I said, you are aware that for 32 and certain brands, the DGTR is looking to initiate antidumping. Antidumping is already initiated by U.S. and a couple of other countries against China. That should hold us in good stead. I hope that addresses this.

Yes. So I mean -- okay. Secondly, on this Packaging segment, if I'm not wrong, by FY '21, we will be having close to 262,000 capacity in overall Packaging segment. So what is the current utilization on these capacity? And what would be the, again, peak revenue expectation from this? And -- yes, please.

So Rohit, I would say that as of now, other than the BOPP plan, which is 60,000 tonnes, which is coming up in Thailand, all of the lines are today commissioned. Now when I look at capacity utilization, other than for Hungary, which is still in, let's say, the position of ramping up and, let's say, some scope available in Thailand, all of the lines are currently operating fully. As I also said during the opening comment, we have now sanctioned a BOPP facility, which is another 60,000 tonnes, which comes up in, let's say, about 20, 25 months. That's the position on capacity utilization.

And any ballpark number on the revenue side? What kind of...

I typically don't give you a comment on revenue numbers because revenues are also a function of the price of key raw material and therefore, it's not fair to give you revenue numbers in that sense. I hope that answers it.

Got it. Got it, sir. And lastly, on Specialty Chemical, I just want to know, we have close to 7%, 8% kind of revenue coming from the domestic market as well. So is it from agri or pharma customer or there is a mix of both? And where we see this percentage share going forward? I mean, what kind of domestic demand is currently evolving in the Specialty Chemical?

So Rohit, over a period of time, what we believe is that the business's focus will remain on exports. There are certain customers who are now looking to set up their agrochemical plants in the country. And to that extent, there will be some of the supplies that will go into the domestic market as well. But largely, I think the focus remains on exports, large innovators and large international customers. For the medium term, at least like 3 to 5 years, I don't see a significant shift in that sense.

Okay. Okay. Got it. And any sense on this QIP money deployment?

I said it in the opening remarks as well. Over a period of time, 12 to 18 months, we will see it mostly deployed into the Specialty Chemicals business, but it will take time. It is not a press of a button that can happen, Rohit.

Rohit, we would request you to please come back in the question here for any follow-up questions as we have several participants waiting for their turn. [Operator Instructions] The next question is from the line of Rohit Nagraj from Sunidhi Securities.

Sir, last time I think you had indicated that the PTFE project has been delayed by 1 year. And then we are starting with the BOPP project, so anything on the PTFE, when is it going to start or whether the dynamics are currently not in favor of this particular product?

So Rohit, we had announced that there would be delay in the PTFE project As of now, we've not reviewed it again. In the next 3 to 6 months, we are scheduled to review this again. We will evaluate whether there is a need to bring that up on a faster basis and then come back to you. As of now, the delay is about 1 year, which is still what we had said earlier as well.

Okay. And the second question is on the BOPP project, so the [indiscernible] CapEx. So would you just give us a broader indication of how the demand is growing in domestic market and how is it in the international market? And how is the demand/supply scenario as of now? So there is no overcapacity and we are predominantly focusing on the Indian market to cater from this particular facility?

So Rohit, the way we are looking at this is that even our BOPP capacity today is fully utilized given on a product mix basis for BOPP. Now we believe that the project will come up onstream in the next 20, 24 months. So let's say 2 years from now. And once that happens, we do believe that about 40% to 50% of the capacity of this plant we can export and the balance is meant for domestic market. Currently, in a 2-year time frame, we see a shortfall in the BOPP market given the current demand/supply dynamics. And therefore, we believe we should be able to sell our lines in a short period of time.

The next question is from the line of Ankit Gor from Systematix.

My question with regards to Chemical division. In light of better product mix, given utilization was better. In OPM, do you think that OPM should have improved in Chemical business? We are still in the '19, '20 range. I assume as you rightly mentioned that [indiscernible] in gas revenue and margin is a little subdued. So better product mix should have improved OPM? My first question is that. What is your sense? Is it just because of the -- towards -- your move from KG to tonne level in many places with many customers or is this a product mix within spectrum?

So Rohit (sic) [ Ankit ], I would say that there are 2 factors in this. Fact is that the revenues of the Specialty Chemical business were significantly subdued as I had mentioned earlier also, both because of certain quantities and the prices of certain key refrigerants. Now given that as a fact, I think that has become a slight drag on the margin. But again, we've said this in the past as well. Even when, let's say, the Specialty Chemicals business was not doing very well, we've seen the Fluorochemicals business do very well. And again, these are business cycles that do play out. I would still say that a 50 basis points increase in operating margin is -- holds us in good stead because as Fluorochemicals ran up in H2, we would see those numbers to be going better. I don't believe it is because of the tonnages and larger quantities that you are referring to has had an impact of this. I do believe that the overall drag on the chemical business is slightly because of the Fluorochemicals business, but I don't see that happening for a very long time.

Okay. Rahul, I'm Ankit from Systematix. My next question with regards to availability of land at the Dahej. For example, you said that INR 750 crore majority will be utilized in [indiscernible]. Do you really have enough land at Dahej for a brownfield or will do greenfield as well in the next 1, 2 years? Any sense on that?

So Rohit (sic) [ Ankit ], I would say that as of now, we believe for the next 3 to 5 years, the CapEx plans that we have, even the increased CapEx plans that we have, we have enough ability to do this at the Dahej site. But given that it takes a long time to look at the land environmental clearances, we can certainly be looking at opportunities. If there is a good sized opportunity in and around Dahej or in any other place, we may look at it. As of now, we don't believe land is a constraint, Rohit (sic) [ Ankit ].

Okay. My last question with regards to BOPP in 16 -- October 16, probably if my memory helps me, you have set up a BOPP of similar size, if I'm not wrong, of about INR 350 crores, INR 370 crores, of the CapEx. So this time around, the CapEx is a pretty big number. So is it just the inflation or better machines, better product mix?

So Rohit (sic) [ Ankit ] again, I don't remember, your memory is better than mine for sure in terms of the cost of the line. But I can tell you that was a 45,000 tonne line. This is a 60,000 tonne line. That was an 8.7 meter line. This is a 10.6 meter line. The advantages of a much larger line, a much larger product mix are something that will play out. So -- and obviously, there will be some cost inflation in terms of the equipment also. But if you look at it from a rated basis, I think it will come out to be pretty similar.

Okay. Coincidentally, PTFE CapEx and this CapEx number is same, INR 424 crores.

No, we made sure that it will always the same. No, I'm just joking.

The next question is from the line of [Sidharth Dandekar] from Equitas.

Sir, just one thing. On the pharma side, in the Specialty Chemical, could you throw some light on what chemicals are we focusing there? And will we be focusing on any therapies also going ahead? Or how is the color in the pharma side is the Specialty Capital business?

So again, Rohit -- sorry, I didn't catch your name.

Siddharth.

Siddharth. Siddharth, I mean, I think the opportunity that we are today seeing in the agrochemical business is very significant. There are multiple chemistries that we are working on not only chlorination but [indiscernible], iodination. Chlorination is something that we have done very well [indiscernible] and others as well, right? But I don't see that as purely a pharmaceutical or agrochemical play. What we are looking at is the overall play in the agrochemical sector seems to be something that we are looking at very significantly. And we believe that is an area that we can grow. We will keep working with pharmaceutical [indiscernible] for their new products. And therefore, that overall piece should expand. But there is no specific chemistry that focuses on pharma or focuses on agri.

So adding pharma in terms of therapies, are we looking at any therapies or we are open to all therapy currently?

There would be about 4, 5. I may not be in a position to give you exact which ones, but yes, there are, let's say, 4, 5 types of therapies that we are looking at.

The next question is from the line of Ankur Periwal from Axis Capital.

Congratulations for the good set of numbers. First question on the chemicals margin side. Now in this quarter, as you alluded towards in your earlier comments as well, there was a certain bit of cost-cutting measures as well apart from...

Ankur, Ankur, Ankur, just a bit slow. I was not able to figure out the question. Could you just repeat please?

Sure. So first thing on the chemical margin side, in your earlier comment in the call you mentioned some cost-cutting measures taken as well plus the favorable product mix, which has led to the margin expansion. Will it be fair to say that this will be a base case margin for us going ahead given rev gas will further see utilization improvements as well as second gains here as well?

So Ankur, I would say the rate like this, that the business remains dynamic, right? So while we do believe that from an overall perspective, there should be incremental numbers that should come through from a margin perspective as fluorochemicals ramps up, The next question that you asked me in what quarter that will happen, that is something that I can't tell you. The only point that I would want to make is that given the fact that the overall, let's say, fluorochemicals business during the quarter and H1 has been muted, as that ramps up, It will again pay out the operating leverage story much better. Therefore, the EBIT margin should typically be on the expanding side.

Sure. So my question was more on the annual run rate side, but fair enough, I got your answer. Second thing here from a -- on the balance sheet side, the working capital, especially the receivables has slightly increased. Anything to focus upon there or any specific segment, which has seen some expansion?

Ankur, I would say the reason for increase is essentially business, right? Because when you look at it, the overall requirement of the large customers is a certain, let's say, number of days or their DSOs are on the higher side. I would also say that typically, my current liabilities would have increased to a certain extent in that sense as well. Now given all of that scenario and given the fact that there were COVID-related issues that were going on, we have had to, let's say, accommodate certain things. where in normal cases, we may not have done that. I do believe if the impact of COVID is run down by the end of March, our working capital should come back to [Audio Gap] has come down because of significant cash flow generation.

The next question is from the line of Amar Moria from [indiscernible].

Hello? Sir, my question is on the packaging film. Sir, packaging film profitability on a sequential basis has improved significantly. Like any color at least for the medium term or a near term, how do we see this behaving in terms of the profitability?

So Ankur, sorry, Amar, what I can tell you is that you've seen very large -- this has been an exceptional quarter. And I probably said the same thing last quarter as well, right? The fact is that some of the new capacities have actually come up. And therefore, the overall margins in the business should be seeing a slight downtrend.

Okay.

At the exit of the year, I don't know where it will be. The only point there is the new resin plant that is coming up in Thailand, which should add to slight margins from an overall perspective from the international BOPP, both operations. The new BOPP line probably comes up in June, July next year. And the new BOPP that we are putting up in India, probably in a [ null 21 ]. So given that as a scenario, I do believe that there will be tapering in margins. I can't give you an exact number as to where we will be. It could be in the range of the revenue side, 3% to 5% from where we are today.

Okay. Okay. Got that. And sir, what would be the technical textile utilization in this particular quarter? And how do we expect it to ramp up because it has been a surprise for us in this particular quarter?

Sorry Amar, no ramp-up happening there. It is already chop a block.

Okay. So meaning you are saying that technical textile is at a key utilization level?

I'm saying at the exit of the quarter, yes.

The next question is from the line of Yogesh Patil from Rajan Securities.

Congratulations for good set of numbers, Rahul. I have 2 questions. First question relates to your 2 projects related to future water security and setup of thermal oxidation facilities. Can you provide how much would be the project cost for both? And if you could throw some light on these projects, how these projects would be ROI accretive and how much ROI you are targeting from these projects? That is my first question.

So I didn't catch your name, please. Rohit?

Yogesh.

Yogesh. Yogesh, if you could just be on mute that will be easier for me because there is a lot of background noise. Thank you, Rohit. See, the point that we are trying to make here is that the overall cost of projects both put together is in the range of about INR 220 crores or so. But the project cost will be incurred over a 3-year period. Now how they are likely to be ROI accretive is the fact that today, even I need to be able to clean out my ATP and clean out my, let's say, the residue from the chemical manufacturer has to be incinerated at a third-party location. There is a certain cost of transportation of that, there is a certain cost of -- there is a certain cost that I need to pay for it. Now when we do a make or buy analysis or do this in-house, we believe that we can do it at a much lower cost. And because of which the thermal oxidation plant obviously becomes much clean ROI project in that sense. Because the cost of doing it outside versus cost of doing it in-house is pretty much in that nature when we have done our calculations. On the water side, the idea is to increase our water capacity over a 2, 3-year period, where we should be in a position to meet the requirement for at least the next 5 to 7 years, from a water perspective. Given the fact that there is a shortage of water in Gujrat, There are certain -- at certain times, the state wants to divert the water from industry to farmers. February, March, we see, in many cases, we see the supply of water to industry being curtailed by the state. We believe that it has led to lower production in certain months from our perspective. And if we are able to secure the water, we should be in a position to actually keep our plants fully running. If that happens, obviously, both become ROI accretive projects. I can't give you exact ROI numbers on it because that's not fair. But yes, they remain ROI accretive is what I can tell you, Yogesh.

Is on the same line. Do you see the same kind of investment is needed for the other chemical facilities in the future to minimize the environment impact?

What other chemical facilities? I only have Dahej and Bhiwadi?

Yes, so in Dahej and Bhiwadi. Yes. So in case of the Bhiwadi?

Bhiwadi, we are not expanding, Yogesh. So I don't see that happening.

The next question is from the line of Surya Patra from PhillipCapital India.

Yes. Congratulations on the great set of numbers, sir. So a couple of questions. First, let's say, on the packaging film business, how should really one look at this business? See, I think having consistently delivered very strong set of margin performance and the kind of a study expansion. So how structural in terms of growth this business could be? And in terms of the increasing or improving product mix, if this is the way that we have added the Thailand facility and now even with miller kind of metal which are basically saying that we are extending here in India. So is it fair to now believe that this packaging film is as structural as chemical business and margin-wise, it is -- it can be slightly fluctuating in nature, but could be progressing, expanding and could be remaining strong and no longer is a volatile business. That is how -- how should one really look at this packaging business because it has now accounts a large chunk of our business and consistently been delivering strong.

So you have answered your question. [Foreign Language] So again, the point is that, again, we've tried to make the business, let's say, cycle proof. But given the fact that there is large capacities that people come up with where there, let's say, demand outgrows -- let's say, supply outgrows demand many times in certain situation, there will be some cyclicality prevailing. Now what I can tell you is that whenever you looked at our line, whenever they have given ounce line, when they have come up, you've seen probably the cycle to be on high, right? I think the ability that we've now developed is to be able to time this well, right? Even the BOPP expansions that we are doing, we believe we will probably be hitting a positive BOPP title going forward. I don't believe that it is as much as the chemical business in terms of, let's say, the margin profiling, there will be positives, but there will also be negatives, let's say, that becomes true. What I can tell you is that when I look at the packaging films business, we have done a lot of work on cost. We have done a lot of work on products. We've done a lot of work with our customers. Our mantra in the business is to be easy to do business with the customers. We've offered sales models to customers which are very innovative in nature, I do believe that our ability to continue the journey in the packaging film business at a pace which is better than my peers will always be there. But will it be cycle proof? I can't say that.

Okay. But sir, at least the metallized product, what we have added in Hungary...

Metallized is pretty much normal here. No, no. Surya, metallized is pretty much normal. Is not just -- so when I say innovative product, it is not just metallized. Metallized is pretty much become standard.